

**MMR**

**Measles, Mumps & Rubella**

# **Measles**

## **(English Measles)**

# Agent


- Agent- RNA virus ( Paramyxovirus family, genus Morbillivirus )
- Source of infection-cases of measles, but not carriers.
- No animal reservoir
- Infective material- Nasal secretion ,Respiratory tract &Throat
- Communicability- Highly infectious during prodromal period and at the time of eruption.
- Secondary attack rate-  $> 80\%$

# Host factors

- Age- 6 months to 3 years even up to 10 years
- Incidence equal in both sexes
- Immunity – life long immunity
- Malnourished children are susceptible

# Environmental factor

- Winter season, over crowding
- Transmission – Droplet infection
- 4 days before and 4 days after rash
- Incubation period- 7 days



Courtesy : Adapted from Mims et al. Medical Microbiology, 1993, Mosby

# Clinical features

- Prodromal stage
- Eruptive stage
- Post-measles stage


# Clinical features

- 3 Cs (Cough, Coryza & Conjunctivitis)
- Koplik spots
- Four days fever (40<sup>0</sup>c)
- Generalized, maculopapular, erythematous rash.





Courtesy : This media comes from the [Centers for Disease Control and Prevention's Public Health Image Library](#) (PHIL), with identification number [#3168](#)



## **KOPLIK SPOT**

Source:

[http://phil.cdc.gov/PHIL/Images/20040908/4f54ee8f0e5f49f58aaa30c1bc6413ba/6111\\_lores.jpg](http://phil.cdc.gov/PHIL/Images/20040908/4f54ee8f0e5f49f58aaa30c1bc6413ba/6111_lores.jpg)



# Complication

- Diarrhea,
- Pneumonia
- Otitis media
- Convulsions,
- SSPE (sub acute sclerosing panencephalitis)

# **WHO** strategy for control and prevention of Measles

- 1) Catch up
- 2) Keep up
- 3) Follow up

# Mumps

The name comes from the British word "to mump", that is grimace or grin.

The appearance of the patient as a result of parotid gland swelling seems to be in grin



Courtesy: This media comes from the [Centers for Disease Control and Prevention](#)'s [Public Health Image Library](#) (PHIL), with identification number [#130](#) Content Providers: CDC/NIP/Barbara Rice

# Agent


- Myxovirus parotidis –RNA virus
- Source of infection – Respiratory, milk
- Period of communicability – 4-6 days of onset of symptoms
- Secondary attack rate – 86%



- Age & sex 5-15 yrs and girls common
- Immunity - life long
- Environmental factor – winter and spring season favors
- Mode of transmission – droplet
- I.P - 2 to 3 weeks

# Clinical features

- Parotid swelling
- Ovaritis
- Pancreatitis
- Ear ache
- Orchitis



Courtesy : Adapted from Mims et al.  
 Medical Microbiology, 1993, Mosby

# Complications

- Orchitis
- Epididymitis
- Oophoritis
- Spontaneous abortion
- Sensori neural hearing loss, (uni- or bilateral).
- Mild form of meningitis
- Encephalitis

# Rubella (German measles)

- The name rubella is derived from a Latin term meaning "little red."
- Rubella is sometime called German Measles or 3-day Measles.
- The synonym "3-day measles" derives from the typical course of rubella exanthema that starts initially on the face and neck and spreads centrifugally to the trunk and extremities within 24 hours.
- It then begins to fade on the face on the second day and disappears throughout the body by the end of the third day.
- It is a generally mild disease caused by the rubella virus.

- Agent – RNA virus (Togo virus family), Genus Rubivirus.
- Source of infection – Respiratory secretion
- Host -3-10 yrs
- Immunity –life long
- Environmental factors –winter and spring season
- Transmission – droplet, vertical transmission
- I.P – 2-3 weeks average 18 days

- Eye pain on lateral and upward eye movement (a particularly troublesome complaint)
- Conjunctivitis
- Sore throat
- Headache
- General body aches
- Low-grade fever
- Chills
- Anorexia
- Nausea
- Tender lymphadenopathy (particularly posterior auricular and suboccipital lymph nodes)
- **Forchheimer sign** (an enanthem observed in 20% of patients with rubella during the prodromal period; can be present in some patients during the initial phase of the exanthem; consists of pinpoint or larger petechiae that usually occur on the soft palate)



## **Temperature**

- Fever is usually not higher than 38.5°C (101.5°F).

## **Lymph nodes**

- Enlarged posterior auricular and suboccipital lymph nodes are usually found on physical examination.

## **Mouth**

- The Forchheimer sign may still be present on the soft palate.



**Image in a 4-year-old girl with a 4-day history of low-grade fever, symptoms of an upper respiratory tract infection, and rash.  
Courtesy of Pamela L. Dyne, MD.**

- 0–28 days before conception - 43% chance
- 0–12 weeks after conception - 51% chance
- 13–26 weeks after conception - 23% chance
- Infants are not generally affected if rubella is contracted during the third trimester




Photo source: U.S. Centers for Disease Control and Prevention


## Rubella syndrome





Microcephaly



PDA



Cataracts




Courtesy

[http://phil.cdc.gov/phil\\_images/20030724/28/PHIL\\_4284\\_lores.jpg](http://phil.cdc.gov/phil_images/20030724/28/PHIL_4284_lores.jpg)

Content Providers(s): CDC Creation

Date: 1976



### **Salt and pepper retinopathy**

<http://www.kellogg.umich.edu/theeyeshaveit/congenital/retinopathy.html>

Courtesy: Jonathan Trobe, M.D. - University of Michigan Kellogg Eye Center

- Sensorineural hearing loss – 58%
- Ocular abnormalities including cataract, infantile glaucoma, Microphthalmia and pigmentary retinopathy occur in approximately 43%
- Congenital heart disease including patent ductus arteriosus (PDA) and pulmonary artery stenosis - 50%

# Measles vaccine

- Live attenuated measles virus (Edmonston-zagreb strain) Propagated on human diploid cell (MRC-5)
- 0.5 ml of vaccine
- Not less than 1000 CCID<sub>50</sub> of measles virus
- 2.5% of gelatin
- 5% of sorbitol as stabilizers
- 0.5 ml of sterile water
- Dose – 0.5 ml
- Route of administration: Sub-cutaneously
- 3 to 5 weeks antibody level – 200mLU/ml



<b>Age</b>	<b>Vaccines</b>	<b>Note</b>
9 months	Measles	Deep subcutaneous injection into the upper arm.
12-15 months	MMR -1	Deep subcutaneous injection into the upper arm.
5 years	MMR -2	Deep subcutaneous injection into the upper arm.